Figure 1.

Cost-effectiveness analysis performed by Leidner and others⁴⁸ comparing treat now versus waiting for disease progression in the general US population using a direct acting antiviral at a cost of $50,000 for a course of treatment for patients with (A) F2 fibrosis, (B) F1 fibrosis, and (C) F0 fibrosis. In a threshold analysis, the cost of treating patients with F0 fibrosis without delay falls to $100,000 per QALY gained at a treatment cost of $42,400 and falls to $50,000 per QALY gained at a treatment cost of $22,200.